MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer

Bing Li(Shanghai Changzheng Hospital), Gerald Schmit-Bindert(Heidelberg University), Caicun Zhou(Tongji University), Fei Ke(Shanghai Pulmonary Hospital), Yayi He(Tongji University), Xuefei Li(Chengdu University of Traditional Chinese Medicine), Yongsheng Wang(Shanghai Pulmonary Hospital), Mo Chen(Tongji University), Songwen Zhou(Tongji University), Peng Kuang(First Affiliated Hospital of University of South China), Lihong Fan(Tongji University), Guanghui Gao(Tongji University), David Garfield(Shanghai Cancer Institute), Shengxiang Ren(Tongji University), Xiaoxia Chen(Shanghai Pulmonary Hospital), Chunxia Su(Tongji University)
Lung Cancer
November 13, 2013
10.1016/j.lungcan.2013.11.003
Cited by 178

Related Papers

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504
Detection and Dynamic Changes of <i>EGFR</i> Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy
|Clinical Cancer Research|2015|469
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|Annals of Oncology|2015|467